Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Daugaard

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 8, 2023
Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trialP L Jørgensen, M Kreiberg, N Jørgensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2022
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upJ Oldenburg, D M Berney, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international studyK Fizazi, J Oldenburg, A Dunant, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2014
Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based studyM G G Kier, J Lauritsen, K Almstrup, et al.
Leukemia & Lymphoma|December 1, 1996
Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell supportH E Johnsen, B Björkstrand, K Carlson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2011
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trialM Bachner, Y Loriot, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancerS Gillessen, E Gallardo, A Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trialB Tombal, A Choudhury, F Saad, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Acta Oncologica (Stockholm, Sweden)|May 8, 2023
Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trialP L Jørgensen, M Kreiberg, N Jørgensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2022
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upJ Oldenburg, D M Berney, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international studyK Fizazi, J Oldenburg, A Dunant, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2014
Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based studyM G G Kier, J Lauritsen, K Almstrup, et al.
Leukemia & Lymphoma|December 1, 1996
Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell supportH E Johnsen, B Björkstrand, K Carlson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2011
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trialM Bachner, Y Loriot, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancerS Gillessen, E Gallardo, A Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trialB Tombal, A Choudhury, F Saad, et al.
Pageof 10